Metabolic syndrome therapy: Prevention of vascular injury by antidiabetic agents

Current Hypertension Reports

Volumn 7, Issue 2, 2005, Pages 110-116

  Dominguez, Ligia J ^a   Sowers, James R ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BENZOIC ACID DERIVATIVE; CHLORPROPAMIDE; DIAZOXIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; GLYCOSIDASE INHIBITOR; INSULIN; LIPID; MEGLITINIDE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; SULFONYLUREA RECEPTOR; TOLBUTAMIDE; TROGLITAZONE; VOGLIBOSE;

ANTICOAGULATION; ANTIHYPERTENSIVE ACTIVITY; BEHAVIOR MODIFICATION; BLOOD RHEOLOGY; BLOOD VESSEL INJURY; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLUCOSE ABSORPTION; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; LIFESTYLE; LIPID METABOLISM; LIVER TOXICITY; MEAL; META ANALYSIS; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; REVIEW; SIDE EFFECT; TREATMENT PLANNING; UNITED STATES; VASCULAR TISSUE; WEIGHT REDUCTION;

EID: 20444407276     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0083-3     Document Type: Review

References (57)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414-1431.
2. Aboderin I, Kaleche A, Ben-Schlomo Y, et al.: Life course perspectives on coronary heart disease, stroke, and diabetes: key issues and implications for policy and research (document WHO/NMH/NPH /01.4). Geneva: World Health Organization; 2001.
3. Sowers JR, Frohlich ED: Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004, 88:63-82.
4. Harris MI: Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000, 23:754-758.
5. Haffner SJ, Cassells H: Hyperglycemia as a cardiovascular risk factor. Am J Med 2003, 115(Suppl 8A):6S-11S.
6. Lane JT: Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. Am J Physiol Renal Physiol 2004, 286:F442-F450.
7. Sowers JR: Obesity as a cardiovascular risk factor. Am J Med 2003, 115(Suppl 8A):37S-41S.
8. UK Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998, 352:837-853.
9. Brayden JE: Functional roles of KATP channels in vascular smooth muscle. Clin Exp Pharmacol Physiol 2002, 29:312-316.
10. Gribble FM, Reimann F: Differential selectivity of insulin secretagogues mechanisms, clinical implications, and drug interactions. J Diabetes Compl 2003, 17:11-15.
11. Keyes L, Rodman DM, Curran ED, et al.: Effect of K+ ATP channel inhibition on total and regional vascular resistance in Guinea pig pregnancy. Am J Physiol 1998, 275:H680-H688.
12. Williams S, Abbott D, Morfis L, et al.: Effects of glibenclamide on blood pressure and cardiovascular responsiveness in noninsulin-dependent diabetes mellitus. J Hypertens 1998, 16:705-711.
13. Sundaresan P, Lykos D, Daher A, et al.: Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM. Diabetes Care 1997, 20:692-697.
14. Abbink EJ, Wollersheim H, Netten PM, et al.: Microcirculatory effects of KATP channel blockade by sulphonylurea derivatives in humans. Eur J Clin Invest 2002, 32:163-171.
15. Ochi H, Ikeda T: Sulphonylureas stimulate renin secretion from the perfused kidney of the rat. Nephron 1999, 81:67-71.
16. Peuler JD, Miller JA, Bourghi M, et al.: Disparate effect of antidiabetic drugs on arterial contraction. Metabolism 1997, 46:1199-1205.
17. Toyoda K, Fuji K, Ibayashi S, et al.: Role of ATP-sensitive potassium channels in brain stem circulation during hypotension. Am J Physiol 1997, 273:H1342-H1346.
18. Jennings PE: Vascular benefits of gliclazide beyond glycemic control. Metabolism 2000, 49(10 Suppl 2):17-20.
19. De Mattia G, Laurenti O, Fava D: Diabetic endothelial dysfunction: effect of free radical scavenging in type 2 diabetic patients. J Diabetes Complications 2003, 17(2Suppl):30-35.
20. Dhindsa P, Davis KR, Donnelly R: Comparison of the micro- and macrovascular effects of glimepiride and gliclazide in metformin-treated patients with type 2 diabetes: a double-blind, crossover study. Br J Clin Pharmacol 2003, 55:616-619.
21. Baron AD: Insulin resistance and vascular function. J Diabetes Complications 2002, 16:92-102.
22. Buse JB, Tan MH, Prince MJ, Erickson PP: The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004, 6:133-156.
23. Katakam PV, Ujhelyi MR, Hoenig M, Miller AW: Metformin improves vascular function in insulin-resistant rats. Hypertension 2000, 35:108-112.
24. Kirpichnipoff D, McFarlane SI, Sowers JR: Metformin: an update: Ann Intern Med 2002, 137:25-33.
25. DeFronzo AM, Goodman RA, for the Multicenter Metformin Study Group: Efficacy of metformin in patients with noninsulin-dependent diabetes mellitus. N Engl J Med 1995, 333:541-549.
26. Fontbonne A, Charles MA, Juhan-Vaghe I, et al.: The effect of metformin on the metabolic abnormalities associated with upper body fat distribution. BIGPRO Study Group. Diabetes Care 1996, 19:920-926.
27. Chen XL, Panek K, Rembold CM: Metformin relaxes rat tail artery by repolarization and resultant decreases in Ca2+ influx and intracellular [Ca2+]. J Hypertens 1997, 15:269-274.
28. Dominguez LJ, Davidoff AJ, Srinivas PR, et al.: Effects of metformin on tyrosine kinase activity glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology 1996, 137:113-121.
29. Ofenstein JP, Dominguez LJ, Sowers JR, Sarnaik AP: Effects of insulin and metformin on glucose metabolism in rat vascular smooth muscle. Metabolism 1999, 48:1357-1360.
30. Pasquali R, Gambineri A, Biscotti D, et al.: Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000, 85:2767-2774.
31. Diabetes Prevention Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
32. Manzella D, Grella R, Esposito K, et al.: Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. Am J Hypertens 2004, 17:223-227.
33. Hundal RS, Krssak M, Dufour S, et al.: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000, 49:2063-2069.
34. Tessier D, Maheux P, Khalil A, Füllöp T: Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism 1999, 48:897-903.
35. Charles MA, Morange P, Eschwège E, et al.: Effect of metformin on weight change and on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care 1998, 21:1967-1972.
36. Kahn CR, Chen L, Cohen SE: Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000, 106:1305-1307.
37. Abrahamson MJ: Clinical use of thiazolidinediones: recommendations. Am J Med 2003, 115(Suppl):116S-120S.
38. Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002, 51:2796-2803.
39. Patti ME, Butte AJ, Crunkhorn S, et al.: Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 2003, 100:8466-8471.
40. Tang WH, Francis GS, Hoogwerf BJ, Young JB: Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003, 41:1394-1398.
41. Bakris G, Viberti G, Weston WM, et al.: Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003, 17:7-12.
42. Aizawa Y, Kawabe J, Hasebe N, et al.: Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 2001, 104:455-460.
43. Haffner SM, Greenberg AS, Weston WM, et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679-684.
44. Gorson DM: Significant weight gain with Rezulin therapy. Arch Intern Med 1999, 159:99.
45. Shinohara E, Kihara S, Ouchi N, et al.: Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. Atherosclerosis 1998, 136:275-279.
46. Takagi T, Yamamuro A, Tamita K, et al.: Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002, 89:318-322.
47. Miyazaki Y, Mahankali A, Matsuda M, et al.: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002, 87:2784-2791.
48. Mayerson AB, Hundal RS, Dufour S, et al.: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002, 1:797-802.
49. Ishizuka T, Itaya S, Wada H, et al.: Differential effects of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 1998, 47:1494-1450.
50. Owens DR, Luzio SD, Ismail I, Bayer T. Increased prandial insulin secretion following a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care 2000, 23:513-523.
51. Hu S, Wang S, Dunning BE: Tissue selectivity of antidiabetic agent nateglinide: study on cardiovascular and beta-cell K[ATP] channels. J Pharmacol Exp Ther 1999, 291:1372-1379.
52. Derosa G, Mugellini A, Ciccarelli L, et al.: Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003, 25:472-484.
53. Scheen AJ: Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003, 63:933-951.
54. Hanefeld M, Cagatay M, Petrowitsch T, et al.: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25:10-16.
55. Hanefeld M, Chiasson JL, Koehler C, et al.: Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004, 35:1073-1078.
56. Chiasson JL, Josse RG, Gomis R, et al. for the STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
57. Grundy SM, Hansen B, Smith SC, et al.: Clinical management of metabolic syndrome. Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on scientific issues related to management. Circulation 2004, 109:551-556.